Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: the PROMISE II Trial

NCT03970538 is registered in ClinicalTrials.gov with LimFlow, Inc. as lead sponsor.

NCT NCT03970538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03970538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: the PROMISE II Trial
Lead sponsor
LimFlow, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
December 6, 2019
Completion date
February 28, 2025
Enrollment
105 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

arterial disease, arterial occlusion, arterial occlusive diseases, chronic limb-threatening ischemia, critical limb ischemia, critical lower limb ischemia, peripheral arterial disease, peripheral artery disease, peripheral artery occlusion, peripheral ischemia, peripheral vascular disease, vascular diseases